IL257723B2 - Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists - Google Patents

Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists

Info

Publication number
IL257723B2
IL257723B2 IL257723A IL25772318A IL257723B2 IL 257723 B2 IL257723 B2 IL 257723B2 IL 257723 A IL257723 A IL 257723A IL 25772318 A IL25772318 A IL 25772318A IL 257723 B2 IL257723 B2 IL 257723B2
Authority
IL
Israel
Prior art keywords
antibody
antigen
patient
binding fragment
secukinumab
Prior art date
Application number
IL257723A
Other languages
English (en)
Hebrew (he)
Other versions
IL257723B (en
IL257723A (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL257723A publication Critical patent/IL257723A/en
Publication of IL257723B publication Critical patent/IL257723B/en
Publication of IL257723B2 publication Critical patent/IL257723B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL257723A 2015-10-19 2016-10-14 Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists IL257723B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562243381P 2015-10-19 2015-10-19
PCT/IB2016/056166 WO2017068472A1 (en) 2015-10-19 2016-10-14 Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists

Publications (3)

Publication Number Publication Date
IL257723A IL257723A (en) 2018-04-30
IL257723B IL257723B (en) 2022-12-01
IL257723B2 true IL257723B2 (en) 2023-04-01

Family

ID=57223732

Family Applications (2)

Application Number Title Priority Date Filing Date
IL257723A IL257723B2 (en) 2015-10-19 2016-10-14 Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists
IL297775A IL297775A (en) 2015-10-19 2016-10-14 Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL297775A IL297775A (en) 2015-10-19 2016-10-14 Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists

Country Status (11)

Country Link
US (2) US20190330328A1 (https=)
EP (1) EP3365011A1 (https=)
JP (4) JP6858766B2 (https=)
KR (1) KR20180064415A (https=)
CN (1) CN108367074A (https=)
AU (4) AU2016342578A1 (https=)
CA (1) CA3002622A1 (https=)
HK (1) HK1251481A1 (https=)
IL (2) IL257723B2 (https=)
RU (2) RU2728710C2 (https=)
WO (1) WO2017068472A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103154031A (zh) 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA3002622A1 (en) * 2015-10-19 2017-04-27 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
CN116059350A (zh) 2015-10-27 2023-05-05 Ucb生物制药有限责任公司 使用抗-il-17a/f抗体的治疗方法
US11299540B2 (en) 2017-06-18 2022-04-12 Kindred Biosciences, Inc. IL17A antibodies and antagonists for veterinary use
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
EP4591879A3 (en) 2019-01-31 2025-10-22 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3963541A1 (en) * 2019-04-29 2022-03-09 UCB Biopharma SRL Medical image analysis system and method for identification of lesions
TW202126329A (zh) * 2019-09-20 2021-07-16 瑞士商諾華公司 使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法
US20240012009A1 (en) * 2020-11-05 2024-01-11 Keyintel Medical Inc. Methods for systematically assessing local inflammation and active repair
EP4471427A1 (en) * 2023-05-31 2024-12-04 Centre Hospitalier Universitaire De Nice Biomarker for spondyloarthitis diagnostic and response to treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013158821A2 (en) * 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
BRPI0706788A2 (pt) 2006-01-31 2011-04-05 Novartis Ag anticorpos antagonistas il-17
BR112013011176A2 (pt) * 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
CA3002622A1 (en) * 2015-10-19 2017-04-27 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013158821A2 (en) * 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PODDUBNYY, DENIS, AND MARTIN RUDWALEIT., ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS–A FIVE-YEAR UPDATE., 31 December 2013 (2013-12-31) *
PODDUBNYY, DENIS., AXIAL SPONDYLOARTHRITIS: IS THERE A TREATMENT OF CHOICE?., 31 December 2013 (2013-12-31) *
SIEPER, JOACHIM, ET AL., EFFICACY AND SAFETY OF ADALIMUMAB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS OF A RANDOMISED PLACEBO-CONTROLLED TRIAL (ABILITY-1)., 31 December 2013 (2013-12-31) *

Also Published As

Publication number Publication date
KR20180064415A (ko) 2018-06-14
HK1251481A1 (zh) 2019-02-01
US20250066466A1 (en) 2025-02-27
JP7389077B2 (ja) 2023-11-29
CN108367074A (zh) 2018-08-03
AU2016342578A1 (en) 2018-03-29
IL257723B (en) 2022-12-01
JP2021100956A (ja) 2021-07-08
AU2021240290A1 (en) 2021-11-11
AU2024278118A1 (en) 2025-01-02
JP6858766B2 (ja) 2021-04-14
RU2018118177A3 (https=) 2020-02-17
RU2018118177A (ru) 2019-11-21
US20190330328A1 (en) 2019-10-31
IL257723A (en) 2018-04-30
JP2023134701A (ja) 2023-09-27
JP2026010006A (ja) 2026-01-21
CA3002622A1 (en) 2017-04-27
JP2018537418A (ja) 2018-12-20
AU2019240551A1 (en) 2019-10-17
EP3365011A1 (en) 2018-08-29
RU2020124276A (ru) 2021-08-03
IL297775A (en) 2022-12-01
RU2020124276A3 (https=) 2022-01-18
WO2017068472A1 (en) 2017-04-27
RU2728710C2 (ru) 2020-07-30

Similar Documents

Publication Publication Date Title
US20250066466A1 (en) Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
JP7591092B2 (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ－１７アンタゴニストの使用
JP2025169269A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して自己免疫疾患を治療する方法
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
HK40110169A (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients